As part of the made-in-Canada approach, we're working very closely with colleagues at Health Canada and the Public Health Agency to try to ensure that we have sufficient domestic capacity on the testing front to be able to support the testing volumes that will be needed by the provinces and territories and the federal government.
I should maybe clarify for the committee members that the specific decisions on how many tests, what kinds of tests and where, and those sorts of things will be made by health authorities. In many cases, those will be provincial and territorial decisions. We obviously, though, want to have a sufficient quantity of testing materials to be able to do that as a country. That's an area where we're working very closely with the National Microbiology Laboratory, our colleagues at Health Canada, the Public Health Agency, and frankly the procurement ministry.
Again, to give you my layperson's explanation, you can think of testing as having very different kinds of tests. There's the lab-based PCR test. That's kind of the gold standard. It's lab-based testing. There are point-of-care tests. We're trying to work across all fronts. Basically, we're going through the list of ingredients and equipment needed for those lab-based tests that are being done and making sure that for every one of those things, we have some line of sight on whether there's Canadian manufacturing capability or whether those ingredients can be sourced in Canada. We don't want to be in a position where some vital constituent part of the test is from a country where there's no supply or it's unreliable or whatever. We're kind of going through the shopping list and making sure we have access to all the ingredients.
We're also—